This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
Intrahepatic cholestasis of pregnancy is characterized by pruritus, elevated bile acids and liver enzymes, and occasionally jaundice. It has specific implications for maternal and perinatal outcomes. Symptomatic and therapeutic treatment with ursodeoxycholic acid is usually initiated. Bile acid levels in their initial and serial determination can assist with antepartum management. Preterm delivery, meconium-stained amniotic fluid, and respiratory distress commonly complicate these pregnancies. The difficulty in predicting and preventing unanticipated fetal death near term drives the obstetrician's desire to deliver infants before 38 weeks. The neonatologist in turn manages potential complications related to prematurity and the compounding negative effect of bile acids on respiratory function. The pathophysiology of elevated maternal bile acid levels on the fetal lung should prompt a high level of care and attention during the first hours after birth in all newborn infants born to women with intrahepatic cholestasis of pregnancy.
- GST-α;
- glutathione S-transferase alpha
- ICP;
- intrahepatic cholestasis of pregnancy
- UDCA;
- ursodeoxycholic acid
- © American Academy of Pediatrics, 2012. All rights reserved.
Individual Login
Institutional Login
You may be able to gain access using your login credentials for your institution. Contact your librarian or administrator if you do not have a username and password.